Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1996-12-17
|
| pubmed:abstractText |
In a double blind pilot study, we examined the effects of the stable prostacyclin derivate taprostene compared to a combination of aspirin and dipyridamole on platelet uptake and clinical outcome after peripheral percutaneous angioplasty. Taprostene was administered to 19 patients as a continuous intravenous infusion from 2 hours before until 8 (n = 6) or 24 (n = 6) hours after angioplasty; 7 control patients were given a combination of 330 mg aspirin and 75 mg dipyridamole. Uptake of 111-indium labelled platelets at the site of the PTA was measured 3 hours before and 4 and 24 hours after angioplasty. Clinical parameters were obtained one day before PTA, on the following day and 3 months after the procedure. There was a tendency for slightly higher platelet uptake ratios in the taprostene groups as compared to the control group especially in patients requiring technically difficult procedures. There were no differences between the 3 groups with regard to primary success or periinterventional complications. In the taprostene patients, 3 early reocclusions were found up to 72 hours after the procedure and 1 late reocclusion within 3 months. In the control group, no reocclusion was apparent in the observation time. No advantages were found when taprostene was administered during angioplasty as compared to conventional treatment with aspirine and dipyridamole.
|
| pubmed:language |
ger
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/Cardiovascular Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Dipyridamole,
http://linkedlifedata.com/resource/pubmed/chemical/Epoprostenol,
http://linkedlifedata.com/resource/pubmed/chemical/taprostene
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0301-1526
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
65-72
|
| pubmed:dateRevised |
2008-2-13
|
| pubmed:meshHeading |
pubmed-meshheading:8851268-Administration, Oral,
pubmed-meshheading:8851268-Adult,
pubmed-meshheading:8851268-Aged,
pubmed-meshheading:8851268-Angioplasty, Balloon,
pubmed-meshheading:8851268-Arterial Occlusive Diseases,
pubmed-meshheading:8851268-Aspirin,
pubmed-meshheading:8851268-Cardiovascular Agents,
pubmed-meshheading:8851268-Dipyridamole,
pubmed-meshheading:8851268-Drug Therapy, Combination,
pubmed-meshheading:8851268-Epoprostenol,
pubmed-meshheading:8851268-Female,
pubmed-meshheading:8851268-Humans,
pubmed-meshheading:8851268-Infusions, Intravenous,
pubmed-meshheading:8851268-Male,
pubmed-meshheading:8851268-Middle Aged,
pubmed-meshheading:8851268-Pilot Projects,
pubmed-meshheading:8851268-Platelet Activation,
pubmed-meshheading:8851268-Recurrence,
pubmed-meshheading:8851268-Treatment Outcome
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
[The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty].
|
| pubmed:affiliation |
Medizinische Klinik und Poliklinik, Technischen Universität München.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
English Abstract,
Randomized Controlled Trial
|